Abstract: A method for treating a microbial infection, especially pneumonia, comprising administering an aqueous-ethanol extract of Thymus or Boswellia or a composition containing the extract. Aqueous-ethanol extracts of Thymus and/or Boswellia.
Abstract: The present invention discloses modified Staphylococcus aureus ClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified ClfA protein.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
November 21, 2023
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Amirreza Faridmoayer, Sabina Marietta Gerber, Stefan Jochen Kemmler
Abstract: Provided herein are compositions comprising Oxalobacter formigenes (Of)-derived factors and variants and fragments thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto.
Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
Type:
Grant
Filed:
October 30, 2020
Date of Patent:
October 31, 2023
Assignee:
Children's Hospital & Research Center at Oakland
Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
Type:
Grant
Filed:
February 8, 2013
Date of Patent:
October 17, 2023
Assignee:
VAR2 Pharmaceuticals APS
Inventors:
Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
Abstract: The present disclosure relates to various different types of mutations in the thrA gene in E. coli leading to enhanced lysine production for, e.g., supplements and nutraceuticals.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
October 17, 2023
Assignee:
Inscripta, Inc.
Inventors:
Eric Abbate, Katherine Krouse, Richard Fox, Daniel Held, Michael Clay, Nandini Krishnamurthy
Abstract: Provided herein are compositions and methods for reducing bacterial contamination during cell culture. Such compositions and methods utilize engineered peptides or recombinant cells capable of secreting such peptides into culture medium. Also provided are methods of using the engineered peptides for inhibiting bacterial growth during culturing of cells.
Type:
Grant
Filed:
June 14, 2021
Date of Patent:
October 17, 2023
Assignee:
Melio Peptide Systems Inc.
Inventors:
Steve Good-Sung Wong, Hendrik Jurgens Jansen Van Vuuren
Abstract: Provided herein are compositions and methods for the treatment of type 1 diabetes (T1D) in mammalian subjects. The compositions include lactic acid fermenting bacteria (LAB) expressing an IL-2 gene and a TID-specific self-antigen (e.g., proinsulin (PINS)) gene. Exemplary methods include: orally administering to a mammalian subject, a therapeutically effective amount of the composition. The composition can be administered to the subject mucosally, resulting in delivery of the LAB into the gastrointestinal tract, where the LAB is released. Bioactive polypeptides expressed by the LAB are thus administered via mucosal delivery. The LAB may be selected to deliver a low-dose of IL-2 to the subject. The methods may not require concomitant systemic anti-CD3 antibody treatment. The methods may be suited for subjects possessing residual beta-cell function, e.g., those with recent-onset T1D.
Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.
Type:
Grant
Filed:
August 25, 2020
Date of Patent:
October 3, 2023
Assignee:
The Regents of the University of California
Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.
Type:
Grant
Filed:
August 26, 2016
Date of Patent:
September 12, 2023
Assignees:
President and Fellows of Harvard College, Massachusetts Institute of Technology, IPSEN PHARMA S.A.S.
Inventors:
R. John Collier, Isaac Chiu, Bradley L. Pentelute, Keith Alan Foster, Shilpa Palan, Sai Man Liu
Abstract: A method for treating a microbial infection, especially pneumonia, comprising administering an aqueous-ethanol extract of Thymus or Boswellia or a composition containing the extract. Aqueous-ethanol extracts of Thymus and/or Boswellia.
Abstract: A method for treating chronic kidney disease, or other renal conditions that has resulted in chronic low-grade activation of the cytokine system in a patient that is in need. Thereof comprising administering botulinum toxin to mitigate the inflammatory state in the kidney. A method of treating acute kidney disease that has resulted from an acute activation of the cytokine system in a patient in need thereof comprising administering nitrous oxide or any inhaled anesthetic in amounts, concentrations, and durations needed to control cytokines and mitigate further damage to healthy kidney tissue.
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
Type:
Grant
Filed:
September 17, 2020
Date of Patent:
August 22, 2023
Assignee:
Pfizer Inc.
Inventors:
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Judith Absalon, Jose Miguel Aste-Amezaga, Johannes Frederik Beeslaar, David Cooper, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Isis Kanevsky, Lakshmi Khandke, Paul Liberator, John Lance Perez, Lynn Marie Phelan, Gary Warren Zlotnick
Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.
Type:
Grant
Filed:
August 22, 2018
Date of Patent:
August 22, 2023
Assignee:
GRIFFITH UNIVERSITY
Inventors:
Michael F. Good, Manisha Pandey, Michael Raymond Batzloff
Abstract: Polypeptides comprising a FimH lectin domain comprising at least one an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.
Type:
Grant
Filed:
January 11, 2022
Date of Patent:
August 15, 2023
Assignee:
JANSSEN PHARMACEUTICALS, INC.
Inventors:
Jan Grijpstra, Marleen Eveline Weerdenburg, Jeroen Geurtsen, Cristhina Kellen Fae, Jakob Louris Feitsma
Abstract: Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.
Abstract: The presently disclosed subject matter provides therapeutic methods and compositions for the treatment of bacterial infections caused by Streptococcus pneumoniae. In particular, methods are provided for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines in a subject in need thereof comprising administering to the subject an effective amount of an agent that inhibits the interaction between a PD-1 ligand and a PD-1 polypeptide. Immunogenic compositions are also provided comprising one or more pneumococcal polysaccharide antigens and an agent that inhibits the interaction between a PD-1 ligand and a PD-1 polypeptide.
Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.
Abstract: Methods of and compositions for breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of an interfering agent capable of specifically competing, titrating, or inhibiting the binding of an HU protein to a microbial DNA. By competing with HU proteins that bind to DNA scaffold in the biofilm, these interfering agents destabilize the biofilm leading to destruction and removal of the biofilm by the immune system. Further method and composition aspects are contemplated in relation to infections caused by bacteria that export an HU protein.
Type:
Grant
Filed:
April 12, 2018
Date of Patent:
July 4, 2023
Assignee:
Research Institute at Nationwide Children's Hospital
Abstract: Compositions and methods for inducing a protective immune response against Coxiella burnetii, to reduce a subject's risk of developing Q fever.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
July 4, 2023
Assignees:
The General Hospital Corporation, EpiVax, Inc., Innatoss Laboratories B.V.
Inventors:
Mark C. Poznansky, Ann Elizabeth Sluder, Timothy Alan Brauns, Anne Searls De Groot, Leonard Jeffrey Moise, Anja Garritsen, Anja Scholzen